Skip to main content

Table 1 Demographic, cognitive and pathological characteristicsa of MAP participants included in the present study

From: Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample

Variable

All participants (n = 308)

NCI (n = 90)

MCI (n = 86)

Dementia (n = 132)

Demographic

    

Female, no. (%)

194 (63 %)

64 (71 %)

48 (56 %)

82 (62 %)

Age at death, years

88.8 ± 6.0

86.8 ± 6.3

88.1 ± 6.4

90.7 ± 5.0

Education, years

14.4 ± 2.8

14.0 ± 2.4

14.7 ± 2.5

14.5 ± 3.2

Race, no. W:AA:NA

300:7:1

86:4:0

84:1:1

130:2:0

APOE ε4 allele, no. (%)

84 (27 %)

15 (17 %)

22 (26 %)

47 (36 %)

PMI, hours

7.2 ± 4.8

6.9 ± 4.4

8.1 ± 5.5

6.7 ± 4.6

Cognitive function proximate to death

    

Global cognition score

−0.85 ± 1.09

0.16 ± 0.41

−0.43 ± 0.45

−1.83 ± 0.88

 Episodic memory

−0.84 ± 1.19

0.34 ± 0.48

−0.55 ± 0.70

−1.84 ± 0.90

 Semantic memory

−0.70 ± 1.23

0.12 ± 0.56

−0.19 ± 0.53

−1.61 ± 1.31

 Working memory

−0.66 ± 1.14

0.16 ± 0.77

−0.29 ± 0.79

−1.50 ± 1.01

 Perceptual speed

−1.13 ± 1.13

−0.28 ± 0.85

−0.70 ± 0.88

−2.02 ± 0.77

 Visuospatial ability

−0.63 ± 1.23

0.12 ± 0.62

−0.16 ± 0.78

−1.49 ± 1.29

MMSE

21.3 ± 8.8

28.1 ± 1.8

25.7 ± 3.8

13.6 ± 8.2

Pathological

    

NIA/Reagan scale, no. in 1:2:3:4b

49:135:120:4

4:25:59:2

4:44:36:2

41:66:25:0

CERAD scale, no. in 1:2:3:4c

95:99:40:74

13:21:19:37

19:31:13:23

63:47:8:14

Braak stage, no. in 0:I:II:III:

4:20:33:91:

2:14:16:33:

2:2:14:28:

0:4:3:30:

IV:V:VI

88: 67:5

21:4:0

30:10:0

37:53:5

Global AD pathology

0.69 ± 0.62

0.38 ± 0.39

0.60 ± 0.57

0.97 ± 0.66

Macroinfarcts, no. (%)

108 (35 %)

20 (22 %)

29 (34 %)

59 (45 %)

Microinfarcts, no. (%)

71 (23 %)

20 (22 %)

14 (16 %)

37 (28 %)

Lewy body disease, no. (%)

27 (9 %)

2 (2 %)

4 (5 %)

21 (16 %)

Hippocampal sclerosis, no. (%)

26 (8 %)

1 (1 %)

5 (6 %)

20 (15 %)

  1. Abbreviations: AA Afro-American, AD, Alzheimer’s disease, BL baseline, CERAD Consortium to establish a registry for AD, MCI mild cognitive impairment, MMSE mini mental state examination, NA Native-American, NCI no cognitive impairment, NIA National Institute on Aging, no number of subjects, PMI postmortem interval, SD standard deviation, W White
  2. aValues are mean ± SD unless noted otherwise
  3. bNIA/Reagan scale: high (1), intermediate (2), low (3), or no (4) likelihood of AD, according to neuritic plaques and tangles
  4. cCERAD scale: definite (1), possible (2), probable (3), or no (4) AD, according to neuritic plaques
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326